Cowen Starts Avalanche Biotechnologies (AAVL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts AAVL Hot Sheet
Price: $4.14 --0%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Join SI Premium – FREE
Cowen initiated coverage on Avalanche Biotechnologies (NASDAQ: AAVL) with an Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Avalanche Biotechnologies click here. For more ratings news on Avalanche Biotechnologies click here.
Shares of Avalanche Biotechnologies closed at $30.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Maxim Group Starts Kyntra Bio (KYNB) at Buy
- B.Riley Starts SmartRent (SMRT) at Buy
- BofA Securities Starts Irsa Inversiones y Rprsntcins SA (IRS) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
